 Erik Oleson
Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dopamine | 24 | 2021 | 281 | 6.460 |
Why?
| | Nucleus Accumbens | 21 | 2020 | 131 | 5.380 |
Why?
| | Avoidance Learning | 6 | 2020 | 66 | 2.410 |
Why?
| | Endocannabinoids | 10 | 2021 | 40 | 2.400 |
Why?
| | Reward | 12 | 2021 | 240 | 2.380 |
Why?
| | Behavior, Animal | 12 | 2018 | 488 | 2.250 |
Why?
| | Cocaine | 12 | 2013 | 156 | 2.000 |
Why?
| | Heroin | 2 | 2020 | 30 | 1.390 |
Why?
| | Cannabinoids | 3 | 2021 | 131 | 1.340 |
Why?
| | Benzoxazines | 3 | 2020 | 31 | 1.320 |
Why?
| | Cannabinoid Receptor Agonists | 5 | 2021 | 36 | 1.290 |
Why?
| | Naphthalenes | 3 | 2020 | 60 | 1.290 |
Why?
| | Motivation | 6 | 2020 | 542 | 1.270 |
Why?
| | Morpholines | 3 | 2020 | 126 | 1.250 |
Why?
| | Dopamine Antagonists | 2 | 2020 | 22 | 1.070 |
Why?
| | Self Administration | 8 | 2013 | 129 | 1.030 |
Why?
| | Rats | 23 | 2020 | 5244 | 1.020 |
Why?
| | Analgesics, Opioid | 2 | 2020 | 917 | 0.810 |
Why?
| | Arachidonic Acids | 4 | 2020 | 56 | 0.780 |
Why?
| | Economics, Behavioral | 2 | 2018 | 9 | 0.760 |
Why?
| | Biological Psychiatry | 1 | 2021 | 2 | 0.740 |
Why?
| | Neuropharmacology | 1 | 2021 | 6 | 0.740 |
Why?
| | Substance Withdrawal Syndrome | 3 | 2021 | 173 | 0.740 |
Why?
| | Psychopharmacology | 1 | 2021 | 9 | 0.720 |
Why?
| | Rats, Long-Evans | 6 | 2020 | 111 | 0.710 |
Why?
| | Cocaine-Related Disorders | 6 | 2012 | 110 | 0.700 |
Why?
| | Drug Tolerance | 1 | 2020 | 82 | 0.700 |
Why?
| | Dopamine Uptake Inhibitors | 2 | 2012 | 57 | 0.680 |
Why?
| | Central Nervous System Stimulants | 2 | 2012 | 153 | 0.660 |
Why?
| | Conditioning, Operant | 6 | 2013 | 104 | 0.650 |
Why?
| | Animals | 36 | 2021 | 34733 | 0.630 |
Why?
| | Diazepam | 2 | 2018 | 26 | 0.610 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2020 | 1969 | 0.560 |
Why?
| | Buprenorphine | 1 | 2020 | 169 | 0.530 |
Why?
| | Receptor, Cannabinoid, CB1 | 3 | 2013 | 38 | 0.520 |
Why?
| | Marijuana Abuse | 3 | 2021 | 230 | 0.490 |
Why?
| | Neurochemistry | 1 | 2014 | 6 | 0.480 |
Why?
| | Reinforcement Schedule | 6 | 2013 | 30 | 0.480 |
Why?
| | Ventral Tegmental Area | 2 | 2013 | 50 | 0.470 |
Why?
| | Escape Reaction | 1 | 2014 | 61 | 0.470 |
Why?
| | Rats, Sprague-Dawley | 12 | 2018 | 2314 | 0.460 |
Why?
| | Consummatory Behavior | 2 | 2010 | 5 | 0.440 |
Why?
| | Biological Clocks | 1 | 2013 | 40 | 0.440 |
Why?
| | Neurotransmitter Agents | 1 | 2013 | 82 | 0.420 |
Why?
| | Punishment | 1 | 2012 | 20 | 0.410 |
Why?
| | Dronabinol | 3 | 2021 | 166 | 0.410 |
Why?
| | Benztropine | 1 | 2012 | 2 | 0.400 |
Why?
| | Histamine H1 Antagonists | 1 | 2012 | 30 | 0.390 |
Why?
| | Cannabinoid Receptor Modulators | 1 | 2012 | 7 | 0.390 |
Why?
| | Fear | 3 | 2018 | 318 | 0.390 |
Why?
| | Glycerides | 3 | 2020 | 15 | 0.390 |
Why?
| | Piperidines | 2 | 2013 | 186 | 0.370 |
Why?
| | GABA-B Receptor Agonists | 1 | 2010 | 4 | 0.360 |
Why?
| | Appetitive Behavior | 1 | 2010 | 8 | 0.360 |
Why?
| | Brain | 4 | 2021 | 2596 | 0.360 |
Why?
| | Dopaminergic Neurons | 3 | 2018 | 55 | 0.340 |
Why?
| | Corpus Striatum | 2 | 2018 | 153 | 0.330 |
Why?
| | Analgesics | 2 | 2020 | 174 | 0.310 |
Why?
| | Motor Activity | 3 | 2013 | 670 | 0.310 |
Why?
| | Male | 27 | 2020 | 63544 | 0.300 |
Why?
| | Cues | 5 | 2018 | 320 | 0.250 |
Why?
| | Electrochemical Techniques | 2 | 2018 | 47 | 0.230 |
Why?
| | Models, Animal | 2 | 2018 | 370 | 0.220 |
Why?
| | Substance-Related Disorders | 1 | 2012 | 1023 | 0.210 |
Why?
| | Carrier Proteins | 4 | 2006 | 730 | 0.190 |
Why?
| | Time Factors | 5 | 2017 | 6593 | 0.180 |
Why?
| | Crime Victims | 1 | 2022 | 105 | 0.180 |
Why?
| | Receptors, Opioid, mu | 1 | 2020 | 57 | 0.170 |
Why?
| | Drug Administration Schedule | 2 | 2020 | 763 | 0.170 |
Why?
| | Extinction, Psychological | 2 | 2018 | 84 | 0.170 |
Why?
| | Administration, Intravenous | 1 | 2020 | 141 | 0.170 |
Why?
| | Optogenetics | 2 | 2018 | 114 | 0.170 |
Why?
| | Sex Offenses | 1 | 2022 | 172 | 0.160 |
Why?
| | Mice, Inbred C57BL | 6 | 2013 | 5279 | 0.160 |
Why?
| | Drug Combinations | 1 | 2020 | 327 | 0.160 |
Why?
| | Sexual and Gender Minorities | 1 | 2022 | 165 | 0.160 |
Why?
| | Mice | 10 | 2021 | 16585 | 0.160 |
Why?
| | N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2018 | 10 | 0.160 |
Why?
| | Serotonin Agents | 1 | 2018 | 8 | 0.160 |
Why?
| | GABA-A Receptor Agonists | 1 | 2018 | 9 | 0.160 |
Why?
| | GABA-A Receptor Antagonists | 1 | 2018 | 16 | 0.160 |
Why?
| | Memory Consolidation | 1 | 2018 | 11 | 0.160 |
Why?
| | Pain Measurement | 1 | 2020 | 497 | 0.150 |
Why?
| | Flumazenil | 1 | 2017 | 6 | 0.150 |
Why?
| | Receptors, GABA-A | 1 | 2018 | 93 | 0.140 |
Why?
| | Central Nervous System Depressants | 2 | 2007 | 82 | 0.130 |
Why?
| | Synaptic Transmission | 2 | 2021 | 258 | 0.120 |
Why?
| | Neurons | 2 | 2014 | 1428 | 0.120 |
Why?
| | Geriatrics | 1 | 2015 | 79 | 0.120 |
Why?
| | Clinical Clerkship | 1 | 2015 | 89 | 0.110 |
Why?
| | Polyunsaturated Alkamides | 1 | 2013 | 7 | 0.110 |
Why?
| | Exploratory Behavior | 2 | 2012 | 85 | 0.110 |
Why?
| | Neuronal Plasticity | 2 | 2006 | 256 | 0.110 |
Why?
| | Education, Medical, Undergraduate | 1 | 2015 | 174 | 0.110 |
Why?
| | Age Factors | 1 | 2020 | 3145 | 0.100 |
Why?
| | Drug-Seeking Behavior | 1 | 2013 | 22 | 0.100 |
Why?
| | Task Performance and Analysis | 1 | 2013 | 176 | 0.100 |
Why?
| | Drug and Narcotic Control | 1 | 2012 | 29 | 0.100 |
Why?
| | Impulsive Behavior | 1 | 2013 | 128 | 0.100 |
Why?
| | Mental Disorders | 1 | 2021 | 1025 | 0.100 |
Why?
| | Spatial Behavior | 1 | 2012 | 23 | 0.100 |
Why?
| | Ethanol | 2 | 2007 | 578 | 0.090 |
Why?
| | Psychomotor Agitation | 1 | 2012 | 65 | 0.090 |
Why?
| | Action Potentials | 1 | 2014 | 463 | 0.090 |
Why?
| | Behavior, Addictive | 1 | 2012 | 84 | 0.090 |
Why?
| | Baclofen | 1 | 2010 | 12 | 0.090 |
Why?
| | Forecasting | 1 | 2012 | 364 | 0.090 |
Why?
| | Haloperidol | 1 | 2010 | 37 | 0.090 |
Why?
| | Fluoxetine | 1 | 2010 | 53 | 0.090 |
Why?
| | Humans | 9 | 2022 | 129705 | 0.080 |
Why?
| | Electroencephalography | 1 | 2012 | 387 | 0.080 |
Why?
| | Mesencephalon | 1 | 2009 | 66 | 0.080 |
Why?
| | Limbic System | 1 | 2009 | 46 | 0.080 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 399 | 0.080 |
Why?
| | Neuropeptides | 1 | 2009 | 70 | 0.080 |
Why?
| | Nerve Net | 1 | 2012 | 249 | 0.080 |
Why?
| | Neuropsychological Tests | 1 | 2013 | 996 | 0.080 |
Why?
| | Databases, Factual | 1 | 2014 | 1297 | 0.080 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2008 | 47 | 0.080 |
Why?
| | Kinetics | 1 | 2012 | 1620 | 0.080 |
Why?
| | Injections, Intravenous | 1 | 2008 | 201 | 0.080 |
Why?
| | Commerce | 1 | 2008 | 68 | 0.070 |
Why?
| | Analysis of Variance | 1 | 2010 | 1288 | 0.070 |
Why?
| | Models, Theoretical | 1 | 2010 | 551 | 0.070 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2009 | 420 | 0.070 |
Why?
| | Glutamic Acid | 2 | 2006 | 227 | 0.070 |
Why?
| | Signal Transduction | 3 | 2021 | 4863 | 0.060 |
Why?
| | Homer Scaffolding Proteins | 4 | 2006 | 5 | 0.060 |
Why?
| | Anesthetics, Local | 1 | 2006 | 85 | 0.060 |
Why?
| | Maze Learning | 1 | 2005 | 93 | 0.060 |
Why?
| | Models, Biological | 2 | 2012 | 1707 | 0.060 |
Why?
| | Frontal Lobe | 1 | 2005 | 146 | 0.060 |
Why?
| | Psychomotor Performance | 1 | 2005 | 312 | 0.050 |
Why?
| | Prefrontal Cortex | 1 | 2005 | 293 | 0.050 |
Why?
| | Memory | 2 | 2018 | 231 | 0.050 |
Why?
| | Algorithms | 1 | 2008 | 1632 | 0.040 |
Why?
| | GABA Modulators | 1 | 2018 | 8 | 0.040 |
Why?
| | Survivors | 1 | 2022 | 458 | 0.040 |
Why?
| | Organ Culture Techniques | 1 | 2018 | 144 | 0.040 |
Why?
| | Microdialysis | 2 | 2009 | 52 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2006 | 2522 | 0.030 |
Why?
| | Mice, Knockout | 3 | 2005 | 2778 | 0.030 |
Why?
| | Protein Isoforms | 2 | 2006 | 369 | 0.030 |
Why?
| | Goals | 1 | 2015 | 162 | 0.030 |
Why?
| | Cannabinoid Receptor Antagonists | 1 | 2013 | 1 | 0.030 |
Why?
| | Gene Deletion | 2 | 2005 | 376 | 0.030 |
Why?
| | Schizophrenia | 2 | 2005 | 433 | 0.020 |
Why?
| | Orexin Receptors | 1 | 2009 | 3 | 0.020 |
Why?
| | Orexins | 1 | 2009 | 5 | 0.020 |
Why?
| | Pyrazoles | 1 | 2013 | 403 | 0.020 |
Why?
| | Receptors, Neuropeptide | 1 | 2009 | 11 | 0.020 |
Why?
| | Naphthyridines | 1 | 2009 | 16 | 0.020 |
Why?
| | Benzoxazoles | 1 | 2009 | 20 | 0.020 |
Why?
| | Electrochemistry | 1 | 2009 | 81 | 0.020 |
Why?
| | Urea | 1 | 2009 | 75 | 0.020 |
Why?
| | Random Allocation | 1 | 2009 | 353 | 0.020 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2009 | 199 | 0.020 |
Why?
| | Caudate Nucleus | 1 | 2007 | 18 | 0.020 |
Why?
| | Putamen | 1 | 2007 | 19 | 0.020 |
Why?
| | Volatilization | 1 | 2007 | 51 | 0.020 |
Why?
| | Receptors, Dopamine D2 | 1 | 2007 | 90 | 0.020 |
Why?
| | Cannabis | 1 | 2012 | 439 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2007 | 676 | 0.020 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2005 | 94 | 0.020 |
Why?
| | Reflex | 1 | 2005 | 67 | 0.020 |
Why?
| | Down-Regulation | 1 | 2007 | 637 | 0.010 |
Why?
| | Drug Synergism | 1 | 2005 | 354 | 0.010 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2006 | 484 | 0.010 |
Why?
| | Neural Inhibition | 1 | 2005 | 151 | 0.010 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2005 | 205 | 0.010 |
Why?
| | Piperazines | 1 | 2005 | 327 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2005 | 1241 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2006 | 1306 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2005 | 1222 | 0.010 |
Why?
| | Alcohol Drinking | 1 | 2005 | 744 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2005 | 2071 | 0.010 |
Why?
| | Phenotype | 1 | 2005 | 3063 | 0.010 |
Why?
| | Female | 3 | 2005 | 68561 | 0.010 |
Why?
|
|
Oleson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|